Eduardo Valdes
Family Medicine · Dallas, TXNPI 1831506179
Payments from drug & device makers
Across 184 payments — averaging $21.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$934
- AstraZeneca$677
- Boehringer Ingelheim$541
- Bayer$384
- GM Pharmaceuticals, Inc.$300
- Merck$120
- plus $990 from 22 others
What the payments were for
- Consulting fees$251%
- Food & beverage$3,92299%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 42 | $934 |
| AstraZeneca | 33 | $677 |
| Boehringer Ingelheim | 29 | $541 |
| Bayer | 11 | $384 |
| GM Pharmaceuticals, Inc. | 1 | $300 |
| Merck | 8 | $120 |
| GSK | 7 | $118 |
| Abbott | 6 | $118 |
| Johnson & Johnson | 6 | $83 |
| Lilly USA, LLC | 6 | $81 |
| Pfizer | 5 | $77 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $66 |
| AbbVie | 3 | $60 |
| Phadia US Inc. | 3 | $44 |
| Genentech USA, Inc. | 3 | $44 |
| Amarin Pharma, Inc. | 2 | $38 |
| Amgen(2 entities) | 2 | $30 |
| Novartis | 2 | $29 |
| Redhill Biopharma Inc. | 2 | $27 |
| Sanofi Pasteur Inc. | 1 | $25 |
| Hologic Sales And Service, LLC | 1 | $24 |
| Gilead | 1 | $23 |
| Exact Sciences | 1 | $21 |
| Shield Therapeutics Inc | 1 | $20 |
| Dexcom, Inc. | 1 | $20 |
| Boston Scientific | 1 | $17 |
| Cumberland Pharmaceuticals, Inc. | 1 | $14 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,947 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 158 | $259,332 |
| RybelsusSemaglutide | 128 | $244,584 |
| FarxigaDapagliflozin Propanediol | 99 | $131,984 |
| OzempicSemaglutide | 29 | $56,465 |
| EliquisApixaban | 29 | $36,344 |
| TradjentaLinagliptin | 23 | $30,116 |
| MounjaroTirzepatide | 15 | $27,935 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $23,755 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $19,633 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $14,951 |
| VascepaIcosapent Ethyl | 11 | $9,012 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $6,539 |
| Gabapentin | 153 | $4,315 |
| Humulin 70-30Insulin Nph Hum/Reg Insulin Hm | 19 | $4,125 |
| PaxlovidNirmatrelvir/Ritonavir | 14 | $2,719 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $934 | $301,049157 claims |
| Boehringer IngelheimJardiance, Tradjenta | $541 | $289,448181 claims |
| AstraZenecaFarxiga | $677 | $131,98499 claims |
| PfizerEliquis, Paxlovid | $77 | $39,06343 claims |
| Lilly USA, LLCMounjaro, Humulin 70-30 | $81 | $32,06034 claims |
| GSKTrelegy Ellipta | $118 | $14,95120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Dallas
- Thomas KingDallas$12M
- Jennifer ZonDallas$5.9M
- Chrisette DharmagunaratneDallas$5.6M
- Michele ReynoldsDallas$3.8M
- Shiwali RaiDallas$2.8M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.